Two Sigma Securities’s Evofem Biosciences, Inc. Common Stock EVFM Stock Holding History

Two Sigma Securities’s Portfolio EVFM Stock Details EVFM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-1,196	Closed	-$6K	–	3015
2022 Q1	$6K	Buy	+1,196	New	+$7.52K	﹤0.01%	2059
2021 Q2	–	Sell	-1,163	Closed	-$31K	–	1795
2021 Q1	$31K	Buy	+1,163	New	+$52.9K	﹤0.01%	757

Other funds holding EVFM

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

FWSM

First Wilshire Securities Management Pasadena, California $444M AUM 42.88% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Two Sigma Securities's EVFM Position: Q2 2022 in Review

Two Sigma Securities sold out of Evofem Biosciences, Inc. Common Stock (EVFM) in Q2 2022, closing a stake of 1,196 shares — an estimated $6K sold.

Two Sigma Securities first reported a position in EVFM in Q1 2021 and held it in 2 quarters. The position peaked at $31K in Q1 2021. 44 funds tracked by Wall St. Rank hold EVFM as of Q2 2022.

Two Sigma Securities reported no remaining Evofem Biosciences, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
Two Sigma Securities sold 1,196 Evofem Biosciences, Inc. Common Stock shares in Q2 2022, an estimated $6K.
Two Sigma Securities first reported a position in Evofem Biosciences, Inc. Common Stock in Q1 2021 and held it in 2 quarters.
Two Sigma Securities's Evofem Biosciences, Inc. Common Stock position peaked at $31K in Q1 2021.
44 funds tracked by Wall St. Rank held Evofem Biosciences, Inc. Common Stock as of Q2 2022.

Based on Two Sigma Securities's 13F filing for Q2 2022, filed 15 Aug 2022.